FundingRounds, leads & terms
London-based Boltz raises $110M Series A for biomolecular AI models in drug discovery
Boltz, a London-based developer of biomolecular AI models for drug discovery, has raised a $110 million Series A without disclosing a valuation. The round follows a $28 million launch financing and a Pfizer partnership as the company reports early lab results.
From the Tech.eu article of November 19, 2026 and cited sources: Boltz has closed a $110 million Series A. [1]
AI-assisted, not human-edited. Methodology Corrections Who owns this site
- What happened
- Boltz has closed a $110 million Series A. [1]
- Original source
- Tech.eu article, independent perspective
- Brief by
- AT Pulse research desk AI-assisted; publisher and contact on the desk page
- When
- November 19, 2026 article published
- Covered
- Nov 19 edition
- Evidence
- 13 sources across 12 sites
- 1London-based Boltz raises $110M Series Atech.eu
- 2Boltz Bags $28M Funding and Pfizer Partnership for…techrepublic.com
- 3Boltz Bags $28M Funding and Pfizer Partnership for…techrepublic.com
- 4Science at the speed of inferencemilled.com
- 5> ## Content Indeximplicator.ai
- 6Product Reports Resources Pricing Login Book a demodealroom.co
Reach: not measured yet

Boltz has closed a $110 million Series A. No valuation was disclosed, so the size of the round is the only financial measure available. [1]
Independent reporting confirms the funding. The 6-of-10 hit rate and the usage growth come from the company and its investors. If they hold up, AI models could shorten early-stage drug discovery, but that is not yet proven.
The rest of the dossier was blocked by a safety filter, so you only have part of it. It stops partway through section 4, "Technical analysis for researchers and developers," and I won't regenerate the withheld part.
What's there:
- The executive brief
- The five-event timeline (June 2025 to November 2026)
- Capabilities and access
- Most of the technical section: Boltz-2's affinity benchmark result, BoltzMol-1's lab results (hits on 6 of 10 targets) and BoltzProt-1's developability figure
What's missing:
- The rest of the technical section, from the reproducibility point onward
- Claims and evidence
- Context and prior work
- Limitations, safety and contested findings
- Business and practitioner implications
- The Sources list
The finished sections cite their sources inline. The round size, the lead investor and the fact that no valuation was disclosed are cited to Boltz's own announcement and Tech.eu's independent report. The usage-growth figure is cited to an a16z post written by investors in Boltz.
The source trail.
Sources (13)
London-based Boltz raises $110M Series A
Article text retrieved; extracted text may omit tables or interactive elements.
tech.euBoltz Bags $28M Funding and Pfizer Partnership for Biomolecular AI Boost - TechRepublic
Web search source
techrepublic.comBoltz Bags $28M Funding and Pfizer Partnership for Biomolecular AI Boost
Web search source
techrepublic.comScience at the speed of inference
Web search source
milled.com> ## Content Index
Web search source
implicator.aiProduct Reports Resources Pricing Login Book a demo
Web search source
dealroom.coBrowse · Organizations
Web search source
latent.spacewww.preqin.com
Web search source
preqin.comBoltz PBC Launches with $28M to Democratize AI Platforms for Drug Discovery
Web search source
hn.jakechampion.nameBiotech News and Headlines
Web search source
pulse.botScience at the speed of inference
Web search source
a16z.newsch.linkedin.com
Web search source
ch.linkedin.comgeo.sig.ai
Web search source
geo.sig.ai